• LAST PRICE
    1.0300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.0100/ 1
  • Ask / Lots
    1.0500/ 1
  • Open / Previous Close
    --- / 1.0300
  • Day Range
    ---
  • 52 Week Range
    Low 0.4500
    High 3.2491
  • Volume
    2,501
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.09
TimeVolumeCUE
09:32 ET47201.07
09:33 ET119001.06
09:35 ET21711.05
09:37 ET20001.05
09:39 ET19371.0403
09:42 ET2001.05
09:44 ET15001.0542
09:46 ET1691.055
09:48 ET9001.06
09:50 ET17421.07
09:51 ET6001.07
09:53 ET40001.07
09:55 ET6731.07
10:02 ET39001.06
10:04 ET16671.0508
10:08 ET10621.0552
10:15 ET9001.065
10:18 ET7001.06
10:22 ET45841.075
10:24 ET107001.07
10:26 ET3001.06
10:31 ET65191.045
10:33 ET12381.05
10:36 ET32001.055
10:38 ET44001.055
10:42 ET8001.055
10:44 ET32001.05
10:47 ET72001.05
10:49 ET15001.055
10:51 ET15001.05
10:54 ET17651.04
10:56 ET17501.0458
11:00 ET32001.045
11:02 ET1001.05
11:05 ET5881.04
11:07 ET96001.04
11:09 ET16001.045
11:12 ET1001.05
11:14 ET3001.04
11:16 ET26291.045
11:18 ET5801.04
11:20 ET100001.04
11:21 ET118711.0306
11:23 ET89001.0301
11:25 ET26201.03
11:27 ET10001.04
11:30 ET14661.04
11:32 ET34501.04
11:34 ET3001.04
11:38 ET8001.05
11:39 ET24001.04
11:41 ET5001.04
11:43 ET30001.045
11:45 ET6201.045
11:56 ET27431.06
11:57 ET1841.0698
11:59 ET1001.065
12:01 ET31001.07
12:03 ET9001.06
12:06 ET10001.06
12:08 ET15001.06
12:17 ET14001.0701
12:19 ET10001.06
12:24 ET2001.065
12:33 ET42561.075
12:37 ET3001.075
12:39 ET1001.07
12:44 ET19401.075
12:46 ET13001.08
12:51 ET23021.0831
12:55 ET2101.085
01:06 ET92001.0813
01:08 ET1001.08
01:11 ET183421.095
01:13 ET1001.09
01:15 ET25001.095
01:18 ET21781.09
01:22 ET1001.08
01:24 ET1001.08
01:29 ET10001.08
01:31 ET9941.09
01:33 ET14001.085
01:38 ET1001.08
01:40 ET4001.08
01:45 ET12831.0839
01:47 ET7761.08
01:49 ET17221.08
01:51 ET1001.08
01:54 ET2001.08
01:56 ET5001.08
01:58 ET3001.08
02:02 ET34081.08
02:03 ET4001.08
02:12 ET3551.07
02:14 ET1001.07
02:16 ET1001.07
02:20 ET1001.07
02:21 ET1001.0701
02:23 ET3001.075
02:25 ET8001.08
02:27 ET2501.09
02:30 ET13161.095
02:32 ET19001.0901
02:34 ET8001.09
02:38 ET7651.08
02:39 ET2001.08
02:41 ET3171.0804
02:45 ET2001.085
02:48 ET8751.08
02:50 ET1001.08
02:52 ET9001.08
02:54 ET5001.08
02:56 ET1001.08
02:57 ET2001.08
02:59 ET1001.08
03:01 ET12001.08
03:03 ET94001.08
03:08 ET6001.08
03:10 ET3001.08
03:12 ET3981.08
03:14 ET1001.08
03:19 ET6001.08
03:21 ET5001.08
03:24 ET133141.075
03:26 ET1001.075
03:30 ET31001.07
03:32 ET4001.075
03:35 ET1001.07
03:39 ET1001.07
03:42 ET1001.07
03:44 ET12301.07
03:46 ET45071.075
03:48 ET3001.0726
03:50 ET24001.07
03:51 ET188451.07
03:53 ET330341.05
03:55 ET517951.055
03:57 ET106501.0378
04:00 ET745861.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCUE
Cue Biopharma Inc
62.0M
-1.1x
---
United StatesKRON
Kronos Bio Inc
52.7M
-0.6x
---
United StatesATRA
Atara Biotherapeutics Inc
60.1M
-0.4x
---
United StatesARMP
Armata Pharmaceuticals Inc
76.0M
-1.7x
---
United StatesCRVO
CervoMed Inc
79.1M
-6.0x
---
United StatesDYAI
Dyadic International Inc
49.2M
-7.6x
---
As of 2024-11-22

Company Information

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

Contact Information

Headquarters
40 Guest StreetBOSTON, MA, United States 02135
Phone
617-949-2680
Fax
302-655-5049

Executives

Independent Chairman of the Board
Frank Morich
President, Chief Scientific Officer
Anish Suri
Chief Executive Officer, Director
Daniel Passeri
Chief Financial Officer
Kerri-Ann Millar
Senior Vice President, General Counsel, Secretary
Colin Sandercock

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$62.0M
Revenue (TTM)
$9.5M
Shares Outstanding
60.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.67
EPS
$-0.91
Book Value
$0.79
P/E Ratio
-1.1x
Price/Sales (TTM)
6.5
Price/Cash Flow (TTM)
---
Operating Margin
-479.42%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.